Sanofi SA

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

31 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

31 май 2024 00:05:00 Источник Nasdaq GlobeNewswire

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

31 май 2024 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

30 май 2024 08:01:34 Источник Nasdaq GlobeNewswire

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

27 май 2024 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

21 май 2024 00:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2024

20 май 2024 15:54:33 Источник Nasdaq GlobeNewswire

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

20 май 2024 13:15:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

13 май 2024 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

10 май 2024 01:00:00 Источник Nasdaq GlobeNewswire

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

02 май 2024 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Annual General Meeting of April 30, 2024

30 апр 2024 11:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

25 апр 2024 00:30:00 Источник Nasdaq GlobeNewswire

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

23 апр 2024 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

17 апр 2024 00:00:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2024

12 апр 2024 13:05:27 Источник Nasdaq GlobeNewswire

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

08 апр 2024 11:00:00 Источник Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

22 мар 2024 01:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - February 2024

15 мар 2024 14:04:03 Источник Nasdaq GlobeNewswire

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

11 мар 2024 01:00:00 Источник Nasdaq GlobeNewswire